风湿性关节炎 (MOOSE) 的甲三口服或皮下注射:多中心随机试验的研究协议
Sarah McClure1, Rebecca Haydock2, Yuanfei Su2
1Nottingham Clinical Trials Unit, The University of Nottingham, Nottingham, UK. sarah.mcclure@nottingham.ac.uk.
Trials
|November 13, 2025
概括
MOOSE试验比较了口服与皮下甲状腺素作为类风湿性关节炎的第一线治疗方法. 这项研究将确定哪种给药途径对患者更有效,更具成本效益.
科学领域:
- 类风湿病学 类风湿病学
- 临床药理学 临床药理学
- 卫生经济学 卫生经济学
背景情况:
- 类风湿性关节炎 (RA) 是一种普遍存在的慢性炎症疾病.
- 口服甲状腺素是标准的第一线治疗,用于不耐受或反应不佳的皮下注射.
- 第一线皮下与口服甲状腺素的比较有效性和成本效益尚未得到充分证实.
研究的目的:
- 为了比较皮下甲状腺素的临床有效性和成本效益与口服甲状腺素作为类风湿性关节炎的第一线治疗.
- 评估RA患者口服和皮下甲状腺 administration route的可接受性.
主要方法:
- 一个开放的标签,多中心,评估者盲目的,双臂随机对照试验 (MOOSE研究).
- 参与者被随机分配到口服或皮下甲索特雷克萨特,根据试验中心,疾病活性和持续时间最小化.
- 主要结局:在24周后缓解. 二次结果:疾病活动,生活质量,心理健康,就业. 包括质量和健康经济评估.
主要成果:
- 关于24周缓解率的初级结果数据正在等待.
- 正在收集有关疾病活动,生活质量,心理健康和就业的二次结果数据.
- 将分析患者和临床医生对服用途径可接受性的定性数据.
结论:
- 这项MOOSE研究解决了关键的临床问题,即对于类风湿性关节炎来说,最佳的第一线甲状腺激素注射途径.
- 生成的证据将为患者和临床医生关于甲状腺素使用的决定提供信息.
- 该研究将提供关于临床有效性,成本效益和可接受性的全面数据.
相关概念视频
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
473
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
473
01:29Therapeutic Drug Monitoring: Affecting Factors
189
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
189
01:15Bioavailability Study Design: Healthy Subjects Versus Patients
137
Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
137
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
470
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
470
01:11Bioavailability Study Design: Single Versus Multiple Dose Studies
189
Bioavailability studies are essential for understanding how a drug is absorbed, distributed, metabolized, and excreted in the body. These studies assess the extent and rate at which the active pharmaceutical agent becomes available at the site of action. The design of bioavailability studies can involve single-dose or multiple-dose regimens, each with distinct advantages and limitations.Single-dose studies are the preferred approach due to their simplicity and reduced drug exposure for...
189
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
420
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
420